輪狀病毒疫苗是預(yù)防輪狀病毒腸炎的疫苗，主要接種對象為年齡較小的兒童。輪狀病毒感染性腹瀉是嬰幼兒急診和死亡(除呼吸道感染之外)的第二位病因，因此，輪狀病毒成為全世界科學(xué)家們研究的焦點(diǎn)。輪狀病毒疫苗是預(yù)防輪狀病毒感染性腹瀉的較經(jīng)濟(jì)、較有效的手段。下面小編為大家分享關(guān)于輪狀病毒疫苗的英語閱讀文章。

Researchers in the African country of Niger have introduced a new vaccine that protects against the diarrheal disease called rotavirus.

非洲國家尼日爾的研究人員推出了一種新型疫苗，可以預(yù)防輪狀病毒腹瀉。

A scientific test has shown that the new vaccine is effective, safe and easy to use. Experts believe it will be more widely used than the two rotavirus vaccines now given to children.

科學(xué)測試表明這種新型疫苗有效、安全、易用。認(rèn)為它將會(huì)比目前對兒童接種的兩種輪狀病毒疫苗使用更為廣泛。

A killer without a good vaccine 缺乏合適疫苗的殺手

The new vaccine is important because rotavirus is a serious illness that can lead to death. Rotavirus causes a severe infection of the gastro-intestinal tract. It kills more than 215,000 children each year -- about 600 a day.

這種新型疫苗非常重要，因?yàn)檩啝畈《臼且环N會(huì)導(dǎo)致死亡的嚴(yán)重疾病。輪狀病毒會(huì)引起胃腸道嚴(yán)重感染。這種病毒每年導(dǎo)致超過21.5萬名兒童死亡，大約相當(dāng)于每天600人。

Two vaccines against rotavirus are already available. However, they are costly and difficult to use.

目前已經(jīng)有兩種針對輪狀病毒的疫苗。然而，這兩種疫苗價(jià)格昂貴并且難以使用。

They must also be kept cold. In many African countries where people suffer from rotavirus, refrigeration and electricity are unreliable.

它們還必須保持低溫。在很多感染輪狀病毒的非洲國家，制冷和電力并不可靠。

As a result, the existing rotavirus vaccines are not widely used.

因此，現(xiàn)有的輪狀病毒疫苗沒有得到廣泛使用。

A new option 新的選擇

Researchers have been working on a new vaccine for rotavirus called BRV-PV. They recently tested the vaccine with young children in Niger.

研究人員一直在研究一種名為BRV-PV的新型輪狀病毒疫苗。他們較近對尼日爾的幼兒測試了這種疫苗。

Researchers gave 1,780 babies the BRV-PV vaccine. Only 31 cases of rotavirus developed in those babies.

研究人員為1780名兒童接種了BRV-PV疫苗。在這些幼兒中只有31人感染了輪狀病毒。

In contrast, 87 cases of rotavirus developed among the babies who received a treatment but did not get the real medicine. In other words, those babies were given a placebo.

相比之下，在接受診治但沒有接種真正疫苗的幼兒之中，有87人感染了輪狀病毒。換句話說，這些幼兒被使用了安慰劑。

The researchers say the clinical trial shows that BRV-PV was nearly 67 percent effective.

研究人員表示，這次臨床試驗(yàn)表明BRV-PV疫苗的有效率接近67%。

The study was published in The New England Journal of Medicine.

這項(xiàng)研究發(fā)表在《新英格蘭醫(yī)學(xué)雜志》上。

更多培訓(xùn)課程： 蘇州個(gè)人提升英語 更多學(xué)校信息： 昆山美聯(lián)英語培訓(xùn) 咨詢電話：